Article

Brimonidine may replace beta-blockers for older patients

Tucson, AZ-Topical beta-blockers have been a mainstay of ongoing treatment for glaucoma for more than 20 years, but a new study adds to the evidence that they may not be the best option for long-term control of IOP for elderly patients.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
Related Content
(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
August 14th 2025

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

3 Things You Should Know About the GA Pipeline
August 14th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/ipopba) Robotic precision: Elevating the state of laser cataract surgery
August 14th 2025

Robotic precision: Elevating the state of laser cataract surgery

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 14th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/NicoElNino) Dialing in precision: Astigmatism management with arcuate incisions
August 14th 2025

Dialing in precision: Astigmatism management with arcuate incisions

(Image credit: Wills Eye Hospital) Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer
August 14th 2025

Wills Eye Hospital names Julia A. Haller, MD, as new chief executive officer

© 2025 MJH Life Sciences

All rights reserved.